Anti-O1 antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-11117956-B2
Application number	US-201716342688-A
Country	US
Kind code	B2
Filing date	Oct 16, 2017
Priority date	Oct 19, 2016
Publication date	Sep 14, 2021
Grant date	Sep 14, 2021

Abstract

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae ). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae ) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae ) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

First claim

What is claimed is:

1. An isolated antigen binding protein that specifically binds to Klebsiella pneumoniae O1 antigen comprising a set of Complementarity-Determining Regions (CDRs): HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 5, and 7, respectively.

2. The isolated antigen binding protein of claim 1 , wherein the LCDR2 comprises the amino acid sequences of SEQ ID NO:6.

3. An isolated antigen binding protein that specifically binds to Klebsiella pneumoniae O1 antigen, wherein the antigen binding protein comprises a VH comprising the amino acid sequence of SEQ ID NO:8 and a VL comprising the amino acid sequence of SEQ ID NO:9.

4. The antigen binding protein of claim 1 , wherein said antigen binding protein is an antibody.

5. The antigen binding protein of claim 1 , wherein said antigen binding protein is an antigen-binding fragment of an antibody.

6. The antigen binding protein of claim 3 , wherein said antigen binding protein is an antibody.

7. The antigen binding protein of claim 3 , wherein said antigen binding protein is an antigen-binding fragment of an antibody.

8. The antigen binding protein of claim 1 , which is a monoclonal antibody.

9. The antigen binding protein of claim 3 , which is a monoclonal antibody.

10. An antigen binding protein produced by (i) culturing a host cell comprising a nucleic acid molecule encoding the antigen binding protein of claim 1 ; and (ii) isolating said antigen binding protein thereof from said cultured host cell.

11. An antigen binding protein produced by (i) culturing a host cell comprising a nucleic acid molecule encoding the antigen binding protein of claim 3 ; and (ii) isolating said antigen binding protein thereof from said cultured host cell.

12. A pharmaceutical composition comprising the antigen binding protein of claim 1 and a pharmaceutically acceptable excipient.

13. A pharmaceutical composition comprising the antigen binding protein of claim 3 and a pharmaceutically acceptable excipient.

14. A pharmaceutical composition comprising the antigen binding protein of claim 4 and a pharmaceutically acceptable excipient.

15. A pharmaceutical composition comprising the antigen binding protein of claim 5 and a pharmaceutically acceptable excipient.

16. The pharmaceutical composition comprising the antigen binding protein of claim 6 and a pharmaceutically acceptable excipient.

17. The pharmaceutical composition comprising the antigen binding protein of claim 7 and a pharmaceutically acceptable excipient.

18. The antigen binding protein of claim 1 , wherein said antigen binding protein induces opsonophagocytic killing (OPK) of Klebsiella and kills Klebsiella via complement dependent killing as measured by a serum bactericidal assay.

19. The antigen binding protein of claim 3 , wherein said antigen binding protein induces OPK killing of Klebsiella and kills Klebsiella via complement dependent killing as measured by a serum bactericidal assay.

20. The antigen binding protein of claim 1 , wherein said antigen binding protein does not neutralize lipopolysaccharide (LPS).

21. The antigen binding protein of claim 3 , wherein said antigen binding protein does not neutralize lipopolysaccharide (LPS).

22. The antigen binding protein of claim 18 , wherein said Klebsiella is multi-drug resistant.

23. The antigen binding protein of claim 19 , wherein said Klebsiella is multi-drug resistant.

24. The antigen binding protein of claim 18 , wherein said Klebsiella is susceptible to antibiotics.

25. The antigen binding protein of claim 19 , wherein said Klebsiella is susceptible to antibiotics.

Assignees

• Medimmune Llc
• Humabs Biomed Sa

Inventors

• Wang Qun
• Stover Charles
• Pennini Meghan
• Chang Chew-Shun
• Xiao Xiaodong
• Hilliard Jamese
• Kaplan Gilad
• Corti Davide
• Cameroni Elisabetta
• Beltramello Martina

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61K39/40

  bacterial · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/31

  multispecific · CPC title